All statistical analyses considered clinical and laboratory parameters obtained at the time of entry to study CCL09101. Differences in the distribution of continuous variables between categories were analyzed by either Mann-Whitney or Kruskal-Wallis test. Patient groups with nominal variables were compared by chi-square test. Survival analysis was considered from the date of study entry to the date of death (uncensored) or last contact (censored). Leukemia-free survival calculations considered leukemic transformation as the uncensored variable. Survival curves were prepared by the Kaplan-Meier method and compared by the log-rank test. Cox proportional hazard regression model was used for multivariate analysis of survival. Logistic regression methods were used for multivariable analysis of response predictors. P values o 0.05 were considered significant. The Stat View (SAS Institute, Cary, NC, USA) statistical package was used for all calculations.
One hundred patients with intermediate-or high-risk MF were enrolled in study CCL09101 at our site (60 and 40 patients in Parts 1 and 2, respectively); 64 patients had PMF, 22 post-polycythemia vera MF and 14 post-essential thrombocythemia MF. Detailed demographic, clinical and laboratory characteristics of this cohort are presented in Table 1 . Twenty-one patients (21%) had been previously treated with an alternative JAK inhibitor; other treatments included thalidomide in 11 patients, pomalidomide in 18 patients and lenalidomide in 11 patients. The momelotinib starting dose was 100 mg/day (n = 3), 150 mg/day (n = 21), 150 mg twice daily (n = 20), 200 mg/day (n = 3), 300 mg/day (n = 47) and 400 mg/day (n = 6). The maximum momelotinib dose achieved was 150 mg/day (n = 6), 150 mg twice daily (n = 20), 300 mg/day (n = 68) and 400 mg/day (n = 6). Seventy-one patients (71%) required dose reduction at some point during treatment. After a median (range) follow-up of 36 months (1-52), 83 patients (83%) had discontinued momelotinib treatment. During the follow-up period, 57 (57%) deaths and 12 (12%) leukemic transformations were recorded.
Eighty-seven patients were evaluable for spleen response and in addition four splenectomized patients were evaluable for liver response; the median (range) palpable spleen size at baseline was 19 cm (6-32). Sixty-eight patients (68%) were evaluable for anemia response; of these 49 patients (49%) were RBC transfusiondependent at study enrollment. Thirty-eight patients achieved a spleen response and one of four splenectomized patients a liver response, for an overall response rate of 43%. Thirty patients (44%) achieved an anemia response, including 25 who were RBC transfusion-dependent at baseline.
Spleen response was correlated with JAK2/MPL/CALR and CALR/ ASXL1 mutational status, with the greatest benefit conferred by CALR mutated status (Table 1) , and, additionally, by smaller palpable spleen (57% vs ⩾ 30% response rate for less or more than the median spleen size; P = 0.02) and constitutional symptoms (absent 57% vs present 34%; P = 0.049). On multivariable analysis, only CALR mutated (hazard ratio (HR) = 0.2, 95% confidence interval (CI) = 0.04-0.6) and ASXL1 unmutated (HR = 0.3, 95% CI = 0.1-0.8) status were independently associated with spleen response. Anemia response was not correlated with mutational status ( 
n/a n/a n/a n/a SRSF2-mutated; n (%); n = 78 14 (17%)
Cytogenetic categories (revised); n Letters to the Editor (normal 70% vs abnormal 38%; P = 0.04) and platelet count (⩾100 × 10 9 /l 59% vs o100 × 10 9 /l 25%; P = 0.05). Absence of CALR (HR = 3.4, 95% CI = 1.2-9.4), and presence of ASXL1 (HR = 2.0, 95% CI = 1.1-3.5) or SRSF2 (HR = 2.6, 95% CI = 1.3-5.0) mutations was associated with inferior survival, independent of age 465 years or DIPSS-plus risk status. Patients who were CALR+ (HR = 0.2, 95% CI = 0.07-0.6) or CALR-/ASXL1 − (HR = 0.5, 95% CI = 0.3-0.9) lived longer than those with CALR-/ASXL1+ mutational status (Figure 1) . This relationship was independent of SRSF2 mutation status (HR = 0.2, 95% CI = 0.1-0.7 and HR = 0.5, 95% CI = 0.3-0.96, respectively), DIPSS-plus risk status (HR = 0.2, 95% CI = 0.1-0.7 and HR = 0.5, 95% CI = 0.3-0.9, respectively) or momelotinib dose (HR = 0.3, 95% CI = 0.1-0.9 and HR = 0.5, 95% CI = 0.3-0.99, respectively). CALR/ASXL1 mutational status did not correlate with leukemia-free survival, which was, however, inferior in 'triple-negative (JAK2-/CALR-/MPL − )' vs CALR+ patients (HR = 13.4, 95% CI = 1.2-153).
Our observations on survival are consistent with recent reports in the general population of patients with MF. 1, 7, 8 In other words, momelotinib treatment was unable to overcome the negative prognostic impact of mutational status in MF. This was also the case with ruxolitinib, another JAK-1/2 inhibitor. 9 However, in contrast to our observation with momelotinib, ruxolitinib-induced spleen response in the latter study, which predated the discovery of CALR mutations, was reported to be independent of mutational status. 9 Regardless, the data from the current study require confirmation from the ongoing larger phase-3 studies of momelotinib therapy in MF. Similarly, it remains to be seen whether our observations are generalizable to other JAK inhibitors. Finally, the basis for the discordance in terms of spleen versus anemia response vis-à-vis CALR mutation status in the current study suggests distinct pathogenetic mechanisms of response. The majority of chronic lymphocytic leukemia (CLL) patients are diagnosed with early-stage disease but the currently used prognostic tools appear to be less informative in this group of patients.
CONFLICT OF INTEREST
1 This is especially problematic for patients with mutated immunoglobulin genes (M-CLL) as they have a more diverse clinical course when compared with patients with unmutated immunoglobulin genes (U-CLL). [1] [2] [3] [4] Given the emergence of promising targeted, less toxic, therapeutics in CLL, 5, 6 there is an increased need to identify patients who might benefit from early treatment with these new agents.
Chemokine receptors expressed on CLL cells are thought to regulate the trafficking of the leukemic cells between blood and lymphoid tissues. 5 Logically, the tendency of CLL cells to return to tissue sites where they are cytoprotected and are driven to proliferate contributes to clinical aggressiveness. It is therefore possible that these receptors represent promising prognostic markers and potentially useful therapeutic targets. We previously reported that one such chemokine receptor, CXCR4, is associated with poor clinical outcome in an unselected cohort of CLL patients. 7 Here we specifically focused our attention on M-CLL samples to ascertain the impact of CXCR4 expression in this clinically heterogeneous subset. The cohort was made up of 60 M-CLL patients from the original study and 64 additional M-CLL patients. The patient characteristics are given in Supplementary Table 1. CXCR4 expression was determined using the three-color flow cytometric assay described previously. 7 We used the median expression as a binary classifier based on receiver operating characteristic analysis. Of the 124 M-CLL samples analyzed, 50 (40.4%) were classified as CXCR4 hi and 74 (59.6%) as CXCR4 lo ; M-CLL patients showed much more heterogeneity in CXCR4 expression than U-CLL (Figure 1a) . Importantly, elevated CXCR4 expression in M-CLL was a strong determinant of reduced overall survival (Figure 1b ; hazard ratio (HR) = 3.5). As M-CLL patients utilizing IGHV3-21 genes have been shown to have an inferior clinical outcome, 8, 9 we asked whether the CXCR4 expression was significantly different in the IGHV3-21 subset. We found no significant increase in CXCR4 expression in IGHV3-21 samples when compared with samples utilizing other IGHV gene segments (Supplementary Figure 1 ; P = 0.92). Similarly, we found no association between CXCR4 expression and the high-risk cytogenetic risk groups (Supplementary Figure 1 ; P = 0.41).
We recently showed a strong association between CXCR4 expression and CD49d in an unselected cohort of U-CLL and M-CLL patients. 7 We therefore examined the expression of CD49d in this M-CLL subset using the same flow cytometric methodology and determined its prognostic relevance. In concordance with our CXCR4 data, there was heterogeneous expression of CD49d with 60 (47.4%) CD49d hi and 64(52.6%) CD49d lo . Again this heterogeneity was in marked contrast to U-CLL cases (Figure 1c) . Furthermore, CD49d hi patients (430% positive) had a significantly worse clinical outcome than CD49d lo patients (Figure 1d ; HR = 3.4) reinforcing the credentials of CD49d as a prognostic marker in the M-CLL subset.
10 When assessed as continuous variables, CXCR4 and CD49d were strongly correlated (Figure 1e ; P o 0.0001). Using categorical cutoffs to define the cohort, the majority of M-CLL cases showed concordant expression for CXCR4 and CD49d: CXCR4 hi /CD49d hi or CXCR4 lo /CD49d lo . However, 27% of the subset was discordant for these markers (Supplementary Figure 2) . The Kaplan-Meier curve for the discordant cases bisected the CXCR4 hi /CD49d hi and CXCR4 lo /CD49d lo curves highlighting the prognostic importance of both CXCR4 and CD49d and suggesting that the combined assessment of CXCR4 and CD49d has clinical utility. This was supported by the observation that the combination of CXCR4 and CD49d was a more powerful prognostic tool than either marker alone for the concordant cases (Figure 1f ; HR = 5.2). It is worthy of note that CXCR4 hi /CD49d hi M-CLL cases had a similar clinical outcome when compared with U-CLL cases (Supplementary Figure 3) .
We went on to establish the functional significance of CXCR4 and CD49d expression in M-CLL. CXCR4
hi /CD49d hi samples showed significantly increased migration in response to CXCL12 in transwell experiments (Figure 2a ; P = 0.012), which could be inhibited by both plerixafor (CXCR4 antagonist) and natalizumab (anti-CD49d antibody) even in the presence of CXCL12 (Figure 2b ). We observed a significant reduction in CXCR4 expression when CLL cells were incubated with CXCL12 presumably owing to the Accepted article preview online 28 October 2014; advance online publication, 18 November 2014
